Sandra Zwiehoff, Astrid Hensel, Ramin Rishmawi, Parisa Shakibaei, Carina Behrends, Katrin Hommel, Christian Bäumer, Shirley Karin Knauer, Beate Timmermann, Christoph Rehbock, Stephan Barcikowski
{"title":"铂纳米敏化剂与临床批准的稳定配体在质子治疗中的协同增强效应,在相关剂量下导致质粒 DNA 的高产率双链断裂","authors":"Sandra Zwiehoff, Astrid Hensel, Ramin Rishmawi, Parisa Shakibaei, Carina Behrends, Katrin Hommel, Christian Bäumer, Shirley Karin Knauer, Beate Timmermann, Christoph Rehbock, Stephan Barcikowski","doi":"10.1002/anbr.202400023","DOIUrl":null,"url":null,"abstract":"<p>Proton therapy is used to eradicate tumors in sensitive areas by targeted delivery of energy. Its effectiveness can be amplified using nanoparticles (NPs) as sensitizers, due to the production of reactive oxygen species at the NP's catalytically active surface, causing the cleavage of DNA. However, the impact of stabilizing macromolecular ligands capping the particles, needed for nanosensitizer dispersion in physiological fluids, is underexplored. Herein, ligand-free colloidal platinum NPs (PtNPs) fabricated by scalable laser synthesis in liquids are used, which allows studying particle and ligand effects separately. PtNPs are incubated with stabilizing concentrations of the clinically approved ligands albumin, Tween, and polyethylene glycol, and irradiated with proton beams at clinically relevant doses (2 and 5 Gy). At these doses, plasmid DNA cleavage larger than 55% of clustered DNA damage is achieved. Bovine serum albumin, Tween, and polyethylene glycol on the NP surface work as double-strand breaks (DSB) enhancers and synergetic effects occur even at low and clinically relevant particle concentrations and irradiation doses. Here, DSB enhancement by ligand-capped PtNP even exceeds the sum of the individual ligand and particle effects. The presented fundamental correlations provide selection rules for nanosensitizer design in proton therapy.</p>","PeriodicalId":29975,"journal":{"name":"Advanced Nanobiomed Research","volume":"4 11","pages":""},"PeriodicalIF":4.0000,"publicationDate":"2024-09-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/anbr.202400023","citationCount":"0","resultStr":"{\"title\":\"Synergetic Enhancing Effects between Platinum Nanosensitizers and Clinically Approved Stabilizing Ligands in Proton Therapy, Causing High-Yield Double-Strand Breaks of Plasmid DNA at Relevant Dose\",\"authors\":\"Sandra Zwiehoff, Astrid Hensel, Ramin Rishmawi, Parisa Shakibaei, Carina Behrends, Katrin Hommel, Christian Bäumer, Shirley Karin Knauer, Beate Timmermann, Christoph Rehbock, Stephan Barcikowski\",\"doi\":\"10.1002/anbr.202400023\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p>Proton therapy is used to eradicate tumors in sensitive areas by targeted delivery of energy. Its effectiveness can be amplified using nanoparticles (NPs) as sensitizers, due to the production of reactive oxygen species at the NP's catalytically active surface, causing the cleavage of DNA. However, the impact of stabilizing macromolecular ligands capping the particles, needed for nanosensitizer dispersion in physiological fluids, is underexplored. Herein, ligand-free colloidal platinum NPs (PtNPs) fabricated by scalable laser synthesis in liquids are used, which allows studying particle and ligand effects separately. PtNPs are incubated with stabilizing concentrations of the clinically approved ligands albumin, Tween, and polyethylene glycol, and irradiated with proton beams at clinically relevant doses (2 and 5 Gy). At these doses, plasmid DNA cleavage larger than 55% of clustered DNA damage is achieved. Bovine serum albumin, Tween, and polyethylene glycol on the NP surface work as double-strand breaks (DSB) enhancers and synergetic effects occur even at low and clinically relevant particle concentrations and irradiation doses. Here, DSB enhancement by ligand-capped PtNP even exceeds the sum of the individual ligand and particle effects. The presented fundamental correlations provide selection rules for nanosensitizer design in proton therapy.</p>\",\"PeriodicalId\":29975,\"journal\":{\"name\":\"Advanced Nanobiomed Research\",\"volume\":\"4 11\",\"pages\":\"\"},\"PeriodicalIF\":4.0000,\"publicationDate\":\"2024-09-06\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://onlinelibrary.wiley.com/doi/epdf/10.1002/anbr.202400023\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Advanced Nanobiomed Research\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://onlinelibrary.wiley.com/doi/10.1002/anbr.202400023\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"ENGINEERING, BIOMEDICAL\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Advanced Nanobiomed Research","FirstCategoryId":"1085","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/anbr.202400023","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"ENGINEERING, BIOMEDICAL","Score":null,"Total":0}
引用次数: 0
摘要
质子疗法通过靶向输送能量来根除敏感区域的肿瘤。利用纳米粒子(NPs)作为增敏剂,可以放大质子疗法的效果,这是因为纳米粒子的催化活性表面会产生活性氧,导致 DNA 断裂。然而,对于纳米增敏剂在生理液体中分散所需的包裹颗粒的稳定大分子配体的影响,还没有进行充分的研究。本文采用在液体中通过可扩展的激光合成技术制造的无配体胶体铂NPs(PtNPs),这样就可以分别研究粒子和配体的影响。PtNPs 与稳定浓度的临床认可配体白蛋白、吐温和聚乙二醇一起培养,并用临床相关剂量(2 和 5 Gy)的质子束照射。在这些剂量下,质粒 DNA 的裂解率大于 55% 的簇状 DNA 损伤。NP表面的牛血清白蛋白、吐温和聚乙二醇可作为双链断裂(DSB)增强剂,即使在低浓度和临床相关的粒子浓度和辐照剂量下也会产生协同效应。在这里,配体封端的铂氮氧化物对 DSB 的增强作用甚至超过了配体和粒子各自作用的总和。所介绍的基本相关性为质子治疗中的纳米增敏剂设计提供了选择规则。
Synergetic Enhancing Effects between Platinum Nanosensitizers and Clinically Approved Stabilizing Ligands in Proton Therapy, Causing High-Yield Double-Strand Breaks of Plasmid DNA at Relevant Dose
Proton therapy is used to eradicate tumors in sensitive areas by targeted delivery of energy. Its effectiveness can be amplified using nanoparticles (NPs) as sensitizers, due to the production of reactive oxygen species at the NP's catalytically active surface, causing the cleavage of DNA. However, the impact of stabilizing macromolecular ligands capping the particles, needed for nanosensitizer dispersion in physiological fluids, is underexplored. Herein, ligand-free colloidal platinum NPs (PtNPs) fabricated by scalable laser synthesis in liquids are used, which allows studying particle and ligand effects separately. PtNPs are incubated with stabilizing concentrations of the clinically approved ligands albumin, Tween, and polyethylene glycol, and irradiated with proton beams at clinically relevant doses (2 and 5 Gy). At these doses, plasmid DNA cleavage larger than 55% of clustered DNA damage is achieved. Bovine serum albumin, Tween, and polyethylene glycol on the NP surface work as double-strand breaks (DSB) enhancers and synergetic effects occur even at low and clinically relevant particle concentrations and irradiation doses. Here, DSB enhancement by ligand-capped PtNP even exceeds the sum of the individual ligand and particle effects. The presented fundamental correlations provide selection rules for nanosensitizer design in proton therapy.
期刊介绍:
Advanced NanoBiomed Research will provide an Open Access home for cutting-edge nanomedicine, bioengineering and biomaterials research aimed at improving human health. The journal will capture a broad spectrum of research from increasingly multi- and interdisciplinary fields of the traditional areas of biomedicine, bioengineering and health-related materials science as well as precision and personalized medicine, drug delivery, and artificial intelligence-driven health science.
The scope of Advanced NanoBiomed Research will cover the following key subject areas:
▪ Nanomedicine and nanotechnology, with applications in drug and gene delivery, diagnostics, theranostics, photothermal and photodynamic therapy and multimodal imaging.
▪ Biomaterials, including hydrogels, 2D materials, biopolymers, composites, biodegradable materials, biohybrids and biomimetics (such as artificial cells, exosomes and extracellular vesicles), as well as all organic and inorganic materials for biomedical applications.
▪ Biointerfaces, such as anti-microbial surfaces and coatings, as well as interfaces for cellular engineering, immunoengineering and 3D cell culture.
▪ Biofabrication including (bio)inks and technologies, towards generation of functional tissues and organs.
▪ Tissue engineering and regenerative medicine, including scaffolds and scaffold-free approaches, for bone, ligament, muscle, skin, neural, cardiac tissue engineering and tissue vascularization.
▪ Devices for healthcare applications, disease modelling and treatment, such as diagnostics, lab-on-a-chip, organs-on-a-chip, bioMEMS, bioelectronics, wearables, actuators, soft robotics, and intelligent drug delivery systems.
with a strong focus on applications of these fields, from bench-to-bedside, for treatment of all diseases and disorders, such as infectious, autoimmune, cardiovascular and metabolic diseases, neurological disorders and cancer; including pharmacology and toxicology studies.